Innopep Inc.

InnoPep Inc. is a company started by a couple of researchers with decades of expertise in peptide synthesis and conjugation aimed at enabling your research by creating the peptides you need. We specialize in quality long peptide synthesis up to 100 amino acids, and we have the technical know-how to make your requests happen. We also have a fully staffed lab right here in San Diego working full time to meet your deadlines.

Publications

• Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models. P.-Y. Yang, et al. (2018) J. Med. Chem. 61: 3218-3223.
• Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate. A.F. Salem, et al. (2018) J. Med. Chem. 61: 2052-2061.
• A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity. L. Zhang, T. Navaratna, and G. M. Thurber (2017) Bioconjugate Chem. 27: 1663-1672.
• Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery P.-Y. Yang, et al. (2016) Proc Natl Acad Sci U S A. 113: 4140-4145.
• hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. E. Barile, et al. (2017) ACS Chem Biol. 12: 444-455.
• Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells. M.-B. Huang, et al. (2017) Oncotarget. 8: 11302-11315.
• Dual-Purpose Linker for Alpha Helix Stabilization and Imaging Agent Conjugation to Glucagon-Like Peptide-1 Receptor Ligands. L. Zhang, T. Navaratna, J. Liang, and G. M. Thurber (2015) Bioconjugate Chem. 26: 329-337.
• Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. B. Wu, et al. (2015) Cell Chem Biol. 22: 876-887.
• Potent and Selective EphA4 Agonists for the Treatment of ALS. B. Wu, et al. (2017) Cell Chem Biol. 24: 293-305.